product summary
Loading...
company name :
Invitrogen
other brands :
NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience
product type :
antibody
product name :
alpha Synuclein Monoclonal Antibody (Syn 211)
catalog :
32-8100
quantity :
100 µg
price :
US 456.00
clonality :
monoclonal
host :
mouse
conjugate :
nonconjugated
clone name :
Syn 211
reactivity :
African green monkey, human, mouse, rat
application :
western blot, ELISA, immunohistochemistry, immunocytochemistry, immunohistochemistry - paraffin section, immunohistochemistry - frozen section, immunohistochemistry - free floating section, western blot knockout validation
more info or order :
Invitrogen product webpage
citations: 39
Published Application/Species/Sample/DilutionReference
  • western blot knockout validation; human; 1:1000; loading ...; fig 6a
  • immunocytochemistry; human; 1:400; loading ...; fig 5b, 8
Zhang S, Eitan E, Wu T, Mattson M. Intercellular transfer of pathogenic α-synuclein by extracellular vesicles is induced by the lipid peroxidation product 4-hydroxynonenal. Neurobiol Aging. 2018;61:52-65 pubmed publisher
  • immunohistochemistry; human; 1:1000; loading ...; fig s2a
Bengoa Vergniory N, Faggiani E, Ramos Gonzalez P, Kirkiz E, Connor Robson N, Brown L, et al. CLR01 protects dopaminergic neurons in vitro and in mouse models of Parkinson's disease. Nat Commun. 2020;11:4885 pubmed publisher
  • immunohistochemistry - free floating section; African green monkey; 1:500; loading ...; fig 1A
Koprich J, Johnston T, Reyes G, Omana V, Brotchie J. Towards a Non-Human Primate Model of Alpha-Synucleinopathy for Development of Therapeutics for Parkinson's Disease: Optimization of AAV1/2 Delivery Parameters to Drive Sustained Expression of Alpha Synuclein and Dopaminergic Degeneration in Macaque. PLoS ONE. 2016;11:e0167235 pubmed publisher
  • western blot; human; fig 2
Caviness J, Lue L, Hentz J, Schmitz C, Adler C, Shill H, et al. Cortical phosphorylated α-Synuclein levels correlate with brain wave spectra in Parkinson's disease. Mov Disord. 2016;31:1012-9 pubmed publisher
  • immunohistochemistry; mouse; fig 1
Kim C, Ojo Amaize E, Spencer B, Rockenstein E, Mante M, Desplats P, et al. Hypoestoxide reduces neuroinflammation and α-synuclein accumulation in a mouse model of Parkinson's disease. J Neuroinflammation. 2015;12:236 pubmed publisher
  • western blot; human; fig 4
Spencer B, Valera E, Rockenstein E, Trejo Morales M, Adame A, Masliah E. A brain-targeted, modified neurosin (kallikrein-6) reduces α-synuclein accumulation in a mouse model of multiple system atrophy. Mol Neurodegener. 2015;10:48 pubmed publisher
  • immunohistochemistry - paraffin section; human; 1:200
Henstridge C, Jackson R, Kim J, Herrmann A, Wright A, Harris S, et al. Post-mortem brain analyses of the Lothian Birth Cohort 1936: extending lifetime cognitive and brain phenotyping to the level of the synapse. Acta Neuropathol Commun. 2015;3:53 pubmed publisher
  • immunohistochemistry; human; 1:1000; fig 1
Bourdenx M, Dovero S, Engeln M, Bido S, Bastide M, Dutheil N, et al. Lack of additive role of ageing in nigrostriatal neurodegeneration triggered by α-synuclein overexpression. Acta Neuropathol Commun. 2015;3:46 pubmed publisher
  • immunocytochemistry; human; 1:500; fig 1
  • western blot; human; 1:250; fig 1
Koch J, Bitow F, Haack J, D Hedouville Z, Zhang J, Tönges L, et al. Alpha-Synuclein affects neurite morphology, autophagy, vesicle transport and axonal degeneration in CNS neurons. Cell Death Dis. 2015;6:e1811 pubmed publisher
  • immunohistochemistry - frozen section; rat; 1:1000
Salganik M, Sergeyev V, Shinde V, Meyers C, Gorbatyuk M, Lin J, et al. The loss of glucose-regulated protein 78 (GRP78) during normal aging or from siRNA knockdown augments human alpha-synuclein (α-syn) toxicity to rat nigral neurons. Neurobiol Aging. 2015;36:2213-23 pubmed publisher
  • immunohistochemistry - free floating section; rat; 1:1000
Reyes J, Rey N, Bousset L, Melki R, Brundin P, Angot E. Alpha-synuclein transfers from neurons to oligodendrocytes. Glia. 2014;62:387-98 pubmed publisher
  • immunocytochemistry; human; 1:1000; fig 4
  • western blot; human; 1:2000; fig 4
Gorbatyuk M, Shabashvili A, Chen W, Meyers C, Sullivan L, Salganik M, et al. Glucose regulated protein 78 diminishes ?-synuclein neurotoxicity in a rat model of Parkinson disease. Mol Ther. 2012;20:1327-37 pubmed publisher
  • western blot; human
Rieker C, Dev K, Lehnhoff K, Barbieri S, Ksiazek I, Kauffmann S, et al. Neuropathology in mice expressing mouse alpha-synuclein. PLoS ONE. 2011;6:e24834 pubmed publisher
  • immunohistochemistry - frozen section; rat; 1:1000
Krumova P, Meulmeester E, Garrido M, Tirard M, Hsiao H, Bossis G, et al. Sumoylation inhibits alpha-synuclein aggregation and toxicity. J Cell Biol. 2011;194:49-60 pubmed publisher
  • western blot; human; 1:1000; fig 6
Schildknecht S, Pape R, Müller N, Robotta M, Marquardt A, Burkle A, et al. Neuroprotection by minocycline caused by direct and specific scavenging of peroxynitrite. J Biol Chem. 2011;286:4991-5002 pubmed publisher
  • immunohistochemistry - paraffin section; human
Fronczek R, Overeem S, Lee S, Hegeman I, van Pelt J, van Duinen S, et al. Hypocretin (orexin) loss in Parkinson's disease. Brain. 2007;130:1577-85 pubmed
Fernandez Espejo E, Rodriguez de Fonseca F, Suarez J, Tolosa E, Vilas D, Aldecoa I, et al. Native α-Synuclein, 3-Nitrotyrosine Proteins, and Patterns of Nitro-α-Synuclein-Immunoreactive Inclusions in Saliva and Submandibulary Gland in Parkinson's Disease. Antioxidants (Basel). 2021;10: pubmed publisher
Cathcart S, Greene E, Powell S, Arumanayagam A, Rivera A, Tawil R, et al. Spinal Cord and Motor Neuron TDP-43 Pathology in a Sporadic Inclusion Body Myositis Patient. J Neuropathol Exp Neurol. 2020;79:1130-1133 pubmed publisher
Alarcón Arís D, Pavia Collado R, Miquel Rio L, Cóppola Segovia V, Ferrés Coy A, Ruiz Bronchal E, et al. Anti-α-synuclein ASO delivered to monoamine neurons prevents α-synuclein accumulation in a Parkinson's disease-like mouse model and in monkeys. EBioMedicine. 2020;59:102944 pubmed publisher
Giguère N, Delignat Lavaud B, Herborg F, Voisin A, Li Y, Jacquemet V, et al. Increased vulnerability of nigral dopamine neurons after expansion of their axonal arborization size through D2 dopamine receptor conditional knockout. PLoS Genet. 2019;15:e1008352 pubmed publisher
Murakami H, Tokuda T, El Agnaf O, Ohmichi T, Miki A, Ohashi H, et al. Correlated levels of cerebrospinal fluid pathogenic proteins in drug-naïve Parkinson's disease. BMC Neurol. 2019;19:113 pubmed publisher
Hawk B, Khounlo R, Shin Y. Alpha-Synuclein Continues to Enhance SNARE-Dependent Vesicle Docking at Exorbitant Concentrations. Front Neurosci. 2019;13:216 pubmed publisher
Taylor Whiteley T, Le Maitre C, Duce J, Dalton C, Smith D. Recapitulating Parkinson's disease pathology in a three-dimensional human neural cell culture model. Dis Model Mech. 2019;12: pubmed publisher
Harischandra D, Rokad D, Neal M, Ghaisas S, Manne S, Sarkar S, et al. Manganese promotes the aggregation and prion-like cell-to-cell exosomal transmission of α-synuclein. Sci Signal. 2019;12: pubmed publisher
Li X, Koudstaal W, Fletcher L, Costa M, Van Winsen M, Siregar B, et al. Naturally occurring antibodies isolated from PD patients inhibit synuclein seeding in vitro and recognize Lewy pathology. Acta Neuropathol. 2019;137:825-836 pubmed publisher
Henrich M, Geibl F, Lee B, Chiu W, Koprich J, Brotchie J, et al. A53T-α-synuclein overexpression in murine locus coeruleus induces Parkinson's disease-like pathology in neurons and glia. Acta Neuropathol Commun. 2018;6:39 pubmed publisher
Tolö J, Taschenberger G, Leite K, Stahlberg M, Spehlbrink G, Kues J, et al. Pathophysiological Consequences of Neuronal α-Synuclein Overexpression: Impacts on Ion Homeostasis, Stress Signaling, Mitochondrial Integrity, and Electrical Activity. Front Mol Neurosci. 2018;11:49 pubmed publisher
Recasens A, Carballo Carbajal I, Parent A, Bove J, Gelpi E, Tolosa E, et al. Lack of pathogenic potential of peripheral ?-synuclein aggregates from Parkinson's disease patients. Acta Neuropathol Commun. 2018;6:8 pubmed publisher
Zunke F, Moise A, Belur N, Gelyana E, Stojkovska I, Dzaferbegovic H, et al. Reversible Conformational Conversion of α-Synuclein into Toxic Assemblies by Glucosylceramide. Neuron. 2018;97:92-107.e10 pubmed publisher
Rockenstein E, Ostroff G, Dikengil F, Rus F, Mante M, Florio J, et al. Combined Active Humoral and Cellular Immunization Approaches for the Treatment of Synucleinopathies. J Neurosci. 2018;38:1000-1014 pubmed publisher
Minakaki G, Menges S, Kittel A, Emmanouilidou E, Schaeffner I, Barkovits K, et al. Autophagy inhibition promotes SNCA/alpha-synuclein release and transfer via extracellular vesicles with a hybrid autophagosome-exosome-like phenotype. Autophagy. 2017;:1-61 pubmed publisher
Carboni E, Tatenhorst L, Tönges L, Barski E, Dambeck V, Bahr M, et al. Deferiprone Rescues Behavioral Deficits Induced by Mild Iron Exposure in a Mouse Model of Alpha-Synuclein Aggregation. Neuromolecular Med. 2017;19:309-321 pubmed publisher
Spencer B, Valera E, Rockenstein E, OVERK C, Mante M, Adame A, et al. Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy. Acta Neuropathol Commun. 2017;5:7 pubmed publisher
Spencer B, Kim C, Gonzalez T, Bisquertt A, Patrick C, Rockenstein E, et al. α-Synuclein interferes with the ESCRT-III complex contributing to the pathogenesis of Lewy body disease. Hum Mol Genet. 2016;25:1100-15 pubmed publisher
Henstridge C, Jackson R, Kim J, Herrmann A, Wright A, Harris S, et al. Erratum to: Post-mortem brain analyses of the Lothian Birth Cohort 1936: extending lifetime cognitive and brain phenotyping to the level of the synapse. Acta Neuropathol Commun. 2015;3:83 pubmed publisher
Taschenberger G, Garrido M, Tereshchenko Y, Bahr M, Zweckstetter M, Kügler S. Aggregation of ?Synuclein promotes progressive in vivo neurotoxicity in adult rat dopaminergic neurons. Acta Neuropathol. 2012;123:671-83 pubmed publisher
Choi J, Park H, Seong Y, Choi E, Min B, Rhim H. Fine epitope mapping of monoclonal antibodies specific to human alpha-synuclein. Neurosci Lett. 2006;397:53-8 pubmed
Sherer T, Betarbet R, Stout A, Lund S, Baptista M, Panov A, et al. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J Neurosci. 2002;22:7006-15 pubmed
Lotharius J, Barg S, Wiekop P, Lundberg C, Raymon H, Brundin P. Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line. J Biol Chem. 2002;277:38884-94 pubmed
product information
Product Type :
Antibody
Product Name :
alpha Synuclein Monoclonal Antibody (Syn 211)
Catalog # :
32-8100
Quantity :
100 µg
Price :
US 456.00
Clonality :
Monoclonal
Purity :
Affinity chromatography
Host :
Mouse
Reactivity :
Human
Applications :
ELISA: Assay-dependent, Immunohistochemistry: Assay-dependent, Western Blot: 1-3 µg/mL
Species :
Human
Clone :
Syn 211
Isotype :
IgG1, kappa
Storage :
-20°C
Description :
Alpha-Synuclein belongs to the Synuclein family, which includes beta and gamma Synuclein, and is predominantly expressed in neurons, and concentrated at synaptic terminals. Synucleins may be involved in the regulation of dopamine release and transport and the modulation of synaptic vesicle function. Alpha-Synuclein is a small, presynaptic protein that is the major nonamyloid component of the pathological inclusions characteristic of a wide range of neurodegenerative disorders, collectively known as synucleinopathies. Alpha-Synuclein is involved in the formation of SNARE complexes, and most significantly, aggregated alpha-synuclein is one of the major components found in the Lewy bodies that occur in Parkinson's disease (PD) and other neurodegenerative disorders. Mutation of the alpha-synuclein gene is associated with familial forms of PD. Alpha-Synuclein is known to reduce the fibrillization of the microtubule-associated protein, tau, to bind various targets such as 14-3-3, protein kinase C, synphilin-1, Elk and Tat-binding protein 1. The alpha and beta synucleins are found primarily in brain tissue where they are seen mainly in neuronal cytosol and presynaptic terminals. The antibody specific for alpha-synuclein does not cross react with beta-synuclein and will be useful for the confirmation of Parkinson's disease and Lewy body dementia and other studies for the localization and detection of alpha-synuclein. Four alternatively spliced transcripts that encode two different isoforms of the alpha-synuclein protein have been identified.
Immunogen :
Recombinant human alpha-synuclein.
Format :
Liquid
Applications w/Dilutions :
ELISA: Assay-dependent, Immunohistochemistry: Assay-dependent, Western Blot: 1-3 µg/mL
Aliases :
Alpha synuclein; alphaSYN; alpha-synuclein; MGC110988; MGC110988 antibody; NACP; NACP antibody; non A-beta component of AD amyloid; non-A beta component of AD amyloid; non-A4 component of amyloid; Non-A4 component of amyloid precursor; OTTHUMP00000218549; OTTHUMP00000218551; OTTHUMP00000218552; OTTHUMP00000218553; OTTHUMP00000218554; PARK 1; PARK 1 antibody; PARK 4; PARK 4 antibody; PARK1; PARK1 antibody; PARK4; PARK4 antibody; PD 1 antibody; PD1; PD1 antibody; Snca; SNCA antibody; Syn; synuclein alpha; synuclein alpha-140; synuclein, alpha; synuclein, alpha (non A4 component of amyloid precursor); SYUA
more info or order :
Invitrogen product webpage
company information
Invitrogen
Thermo Fisher Scientific
81 Wyman Street
Waltham, MA USA 02451
https://www.thermofisher.com
800-678-5599
headquarters: USA